PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
2023 · Molecular Cancer · 1,724 citations
https://doi.org/10.1186/s12943-023-01827-6
J
Jyothi S. Prabhu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
94
Papers
2.5K
Citations
16
h-index
25
i10-index
Jyothi S. Prabhu is an academic researcher from St. John's University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Cancer Cells and Metastasis & Breast Cancer Treatment Studies. The author has an h-index of 16, co-authored 80 publications.
ORCID: 0000-0002-2269-3704Papers by this author
worksHigh expression of integrin <i>β</i>6 in association with the Rho–Rac pathway identifies a poor prognostic subgroup within <scp>HER</scp>2 amplified breast cancers
2016 · Cancer Medicine · 41 citations
https://doi.org/10.1002/cam4.756
miR‐18a activates Wnt pathway in ER‐positive breast cancer and is associated with poor prognosis
2020 · Cancer Medicine · 26 citations
https://doi.org/10.1002/cam4.3183
High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis
2021 · Cancer Treatment and Research Communications · 18 citations
https://doi.org/10.1016/j.ctarc.2021.100321
Increased prevalence of hybrid epithelial/mesenchymal state and enhanced phenotypic heterogeneity in basal breast cancer
2024 · iScience · 16 citations
https://doi.org/10.1016/j.isci.2024.110116
HR+HER2− breast cancers with growth factor receptor–mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells
2017 · Tumor Biology · 12 citations
https://doi.org/10.1177/1010428317695028
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat